

GSK delivers strong Q1 2022 sales of £9.8 billion, +32% CER




Biopharma

£7.1bn
+ 40%

Consumer Healthcare

£2.6bn
+ 14%



28.6%

Total Group operating margin

26.7%

Adjusted Group operating margin

35.9p
+ 66%

Total EPS

32.8p
+ 43%

Adjusted EPS

£1.7bn

Free cash flow

14p

Dividend



Emma Walmsley
CEO, GSK

“We have delivered strong first quarter results in this landmark year for GSK, as we separate Consumer Healthcare and start a new period of sustained growth. Our results reflect further good momentum across specialty medicines and vaccines and continuing pipeline progress. We also continue to see very good momentum in Consumer Healthcare, demonstrating strong potential of this business ahead of its proposed demerger in July, to become Haleon.”

All % at constant exchange rates (CER)
Journalists/media see press release on www.gsk.com for full details on Q1 2022.
Please read the cautionary statement regarding **forward-looking statements** and the definitions and reconciliations for non-IFRS measures on pages 42 to 43 of the first quarter press release.